These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 8151323)

  • 1. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
    J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacarbazine and interferon alpha for stage IV malignant melanoma.
    Tamm I; Grimme H; Bergen E; Simon JC; Schöpf E; Mertelsmann R; Lindemann A; Brennscheidt U
    Oncology; 1997; 54(4):270-4. PubMed ID: 9216849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
    Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
    Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
    Hersey P; McLeod GR; Thomson DB
    Br J Haematol; 1991 Oct; 79 Suppl 1():60-6. PubMed ID: 1931712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
    Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
    Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
    Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
    Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
    Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
    Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
    Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
    J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
    Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R
    Melanoma Res; 2003 Feb; 13(1):87-91. PubMed ID: 12569290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
    J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.
    Ron IG; Inbar MJ; Gutman M; Merimsky O; Chaitchik S
    Cancer Immunol Immunother; 1993 Jul; 37(1):61-6. PubMed ID: 8513453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
    J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
    Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
    Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
    Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
    Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.